About the Company
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SPPI News
Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million
Spectrum Pharmaceuticals Inc. (SPPI) popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech ...
Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval
Now let's look at TheStreet Ratings' take on this stock. TheStreet Ratings team rates SPECTRUM PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about ...
SHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) Investors
A class action securities lawsuit was filed against Assertio Holdings, Inc. (ASRT) that seeks to recover losses of Assertio Holdings shareholders who were adversely affected by alleged securities ...
Assertio Scoops Up Spectrum Pharma In $248M Stock Deal
Assertio Holdings Inc (NASDAQ: ASRT) will acquire Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) in an all-stock and contingent value rights (CVR) transaction. Under the terms of the agreement ...
Assertio 48 Hour Deadline Alert
In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon (the ...
Assertio Deadline Alert
In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon (the ...
Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction
today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. (“Spectrum”) (Nasdaq: SPPI), a biopharmaceutical company focused on novel and targeted oncology.
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $92.75, along ...
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company ... The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that ...
Spectrum Pharmaceuticals In Deal With Viropro For Cancer Drug
Spectrum Pharmaceuticals Inc. (SPPI) signed a deal with biopharmaceutical company Viropro Inc. (VPRO) to develop a biosimilar version of Swiss pharmaceutical giant Roche Holding AG's (RHHBY ...
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP ... Dr. Kevin Garey presented on behalf of the Company at ID Week with selective spectrum of activity data ...
Q4 2023 Acurx Pharmaceuticals Inc Earnings Call
Michael Okunewitch; Senior Research Analyst; Maxim Group LLC, Research Division ...
Loading the latest forecasts...